Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Pandion Therapeutics, Inc. (PAND)
|
|
| Common Size Income Statement |
|
|
|
|
Annual | Quarterly | TTM |
|
| In millions, except per share items | Dec-31-20 | Sep-30-20 | Jun-30-20 | Mar-31-20 | Dec-31-19 | Sep-30-19 | Jun-30-19 | Mar-31-19 |
| | 10-K | 10-Q | 10-Q | S-1/A | 10-K | 10-Q | 10-Q | S-1/A |
| Revenues | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | | | 100.0% |
| Cost of goods sold | 0.0% | 0.0% | 0.0% | 2397.7% | 0.0% | | | 131.7% |
| Gross profit | 100.0% | 100.0% | 100.0% | -2297.7% | 100.0% | | | -31.7% |
| Research and development | 402.4% | 352.8% | 453.2% | | 390.0% | | | |
| General and administrative | 210.1% | 164.7% | 117.5% | 518.1% | 193.8% | | | 31.7% |
| Depreciation | 8.4% | 6.0% | 8.7% | | 6.7% | | | |
| EBIT | -512.5% | -417.6% | -470.7% | -2297.7% | -483.8% | | | -131.7% |
| Pre-tax income | -511.9% | -426.7% | -472.5% | -2262.4% | -469.8% | | | -129.8% |
| Income taxes | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | | | 0.0% |
| Net income | -511.9% | -452.0% | -611.2% | -2.7% | -574.5% | | | -0.2% |
|